BARER SOL J 4

What Happened

• Sol J. Barer, a director of Teva Pharmaceutical Industries Ltd (TEVA), had 21,739 restricted share units (RSUs) vest and convert into 21,739 ordinary shares on June 5, 2026. The Form 4 records an acquisition of 21,739 shares (price listed as N/A) and a simultaneous disposition of 21,739 shares at $0.00 (derivative transaction code M).
• The acquisition reflects RSU settlement; the immediate disposition of the same number of shares at $0.00 is consistent with shares being withheld/surrendered to satisfy tax withholding or settlement requirements, resulting in no net increase in shares held by the insider.

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-08 (appears timely).
• Acquired: 21,739 shares (conversion of RSUs) — price N/A.
• Disposed: 21,739 shares — price $0.00 (derivative disposition).
• Shares owned after transaction: not disclosed in this filing.
• Footnotes: F1 notes ordinary shares may be represented by American Depositary Shares (ADS); F2 explains each RSU equals a contingent right to one ordinary share (or cash at committee option); F3 confirms RSUs were granted 2025-06-05 and vested 2026-06-05.
• Transaction code: M (conversion/exercise of derivative security); disposition at $0.00 commonly reflects tax withholding or share surrender (reported as a derivative transaction).

Context

• This appears to be a routine RSU vest-and-settle event rather than an open-market buy or sell intended as a market signal. When RSUs vest, companies often withhold or surrender shares to cover taxes or exercise costs; that is likely what occurred here given the equal acquire/dispose amounts and $0.00 disposal price.
• No cash purchase or sale value was reported, and there is no indication of a 10% owner transaction or a 10b5-1 plan in this filing.